Lanterne Dx Completes Merger with Flagship Biosciences, Expanding Biomarker and Digital Pathology Capabilities

Barchart · 4d ago

Boulder, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Lanterne Dx, LLC, a discovery and clinical phase CRO offering histopathology and biomarker validation services to pharmaceutical and biotech customers, today announced it has completed its merger with Flagship Biosciences, Inc., a computational biology, data science, and digital pathology company backed by Ampersand Capital Partners. The combined organization will operate under the Lanterne Dx name.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.